Prostate cancer is the most common malignancy in men. Although patients with metastatic prostate cancer can benefit from androgen ablation, most of them will die of prostate cancer progression to an androgen-refractory state. In the present study, the effects of docetaxel, bevacizumab, 5-fluorouracil (5-FU), bevacizumab plus docetaxel, and bevacizumab plus 5-FU on the growth of human CWR-22 (androgen-dependent) and CWR-22R
Introduction
Prostate cancer represents the most common disease in men worldwide and is the second cause of death from malignant cancers (1, 2) . The clinical outcome of prostate cancer is strongly correlated to its differentiation and tumor grade (3) . Whereas patients with localized disease may be cured with surgery or radiation, most patients respond initially to ablation of gonadal androgen production through either orchiectomy or luteinizing hormone -releasing hormone agonists (4) . Eventually, most patients will develop progressive disease despite continued androgen suppression. The main options currently available for hormonerefractory prostate cancer are second-line hormonal manipulations, radiation therapy, traditional cytotoxic chemotherapy, and investigational therapy with novel and targeted agents (5) . Currently, docetaxel plus prednisone is a standard second-line therapy for hormone-refractory prostate cancer patients (reviewed in ref. 6 ).
Prostate cancer arises from multiple genetic and epigenetic aberrations (7) . Common aberrations in human prostate cancer are reduced expression of pRb (8) and frequent inactivation of phosphatase and tensin homologue (PTEN; ref. 9 ). The degree of PTEN deficiency is closely correlated with activation of the oncogenic kinase Akt (10) . Akt activation affects cell cycle progression through regulation of cyclin D stability and mRNA translation via control of phosphorylation of eukaryotic translation initiation factor 4E -binding protein 1 (4E-BP1) and its dissociation from the mRNA cap binding protein eukaryotic translation initiation factor 4E (11) . Targeting of activated Akt to mouse prostate induces prostate intraepithelial neoplasia, which is reversed following administration of the mammalian target of rapamycin (mTOR) inhibitor RAD001 (12) . It has been reported that the growth and proliferation of tumors expressing constitutive activation of phosphatidylinositol 3-kinase and Akt or inactivation of PTEN displayed enhanced sensitivity to mTOR inhibitors (reviewed in ref. 13 ). Recent studies have found that mTOR activation is also important for the secretion of vascular endothelial growth factor (VEGF; ref. 14) .
Prostate cancer specimens show increased VEGF expression and vascularity when compared with benign prostatic hyperplasia and normal prostate tissue (15) . An association does exist between microvessel density in tumor, Gleason score, metastases, tumor aggressiveness, and progression (16 -18) . VEGF levels correlate with disease stage and perhaps survival in the metastatic setting and hormonerefractory prostate cancer (19) . In the CWR-22 prostate cancer xenograft model, the addition of paclitaxel enhances the antitumor activity of monoclonal VEGF antibody (20) . The safety and efficacy of bevacizumab/docetaxel/ estramustine combination for hormone-refractory prostate cancer (reviewed in ref. 21 ) and of bevacizumab/irinotecan/5-fluorouracil (5-FU)/leucovorin combination for metastatic colorectal cancer (22) have been reported. Several antiangiogenic agents are under investigation in clinical trials for prostate cancer, including thalidomide (23), thalidomide analogues (24, 25) , and VEGF receptor inhibitors such as AZD6474, KRN633, and CEP-7055 (reviewed in ref. 26) .
In the present study, we show that addition of bevacizumab to 5-FU -based chemotherapy potently inhibits tumor growth, angiogenesis, cell cycle progression, and the Akt/mTOR pathway. This combination holds a promise as an adjuvant to conventional therapies. The study received ethics board approval from the National Cancer Centre of Singapore and Singapore General Hospital. All mice were maintained according to the ''Guide for the Care and Use of Laboratory Animals'' published by NIH. They were provided with sterilized food and water ad libitum and housed in negative pressure isolators with 12-h light/dark cycles.
Materials and Methods

Docetaxel
Prostate cancer xenografts were carried out with male severe combined immunodeficient (SCID) mice of 9 to 10 weeks of age (Animal Resources Centre, Canning Vale, West Australia). Androgen-dependent human CWR-22 (27) and androgen-independent CWR-22R (28) prostate cancer xenografts were minced under sterile conditions. Approximately 1 Â 10 7 cells were s.c. implanted in both flanks of male SCID.
To investigate the effects of bevacizumab, docetaxel, and 5-FU on the growth of prostate cancer xenografts, these drugs were diluted in saline solution at an appropriate concentration. Mice bearing tumor xenografts were divided into five groups and each consisted of 12 mice. They were i.p. injected with 100 AL of saline, 5 mg/kg bevacizumab every 2 weeks (29), or weekly with 12.5 mg/kg 5-FU (30), 10 mg/kg docetaxel (two doses in total at one-week interval as described; ref. 31) , bevacizumab plus 5-FU, or bevacizumab plus docetaxel for 21 days. Treatments started on day 7 after tumor implantation. By this time, the tumors had reached the size of f100 mm 3 . Tumor growth was monitored every 2 days by vernier caliper measurement of the length (a) and width (b) of the tumor. Tumor volume was calculated as (a Â b 2 )/2. The animals were sacrificed on day 21 during the treatment because the tumor size in the controls exceeded 1,500 mm 3 in accordance with the animal care protocol. Body weight and tumor weight were recorded, and tumors harvested for later analysis.
Efficacy of antitumor agents was determined by %T/C, where T and C are the median tumor weight (in milligrams) of drug-treated and vehicle-treated mice at day 21 during the treatment, respectively. Ratios of V42% are considered an active response (Drug Evaluation Branch of the Division of Cancer Treatment, National Cancer Institute criteria).
Immunohistochemistry Five-micrometer sections were dewaxed, rehydrated, and subjected to antigen retrieval. After blocking endogenous peroxidase activity and nonspecific staining, the sections were incubated with antibodies against Ki-67, CD31, and cleaved caspase-3 (overnight at 4jC). Immunohistochemistry was done using the streptavidin-biotin peroxidase complex method according to the manufacturer's instructions (Lab Vision) using 3,3 ¶-diaminobenzidine as the chromogen. Sections known to stain positively were incubated in each batch and negative controls were also prepared by replacing the primary antibody with preimmune sera. For Ki-67, only nuclear immunoreactivity was considered positive. The number of labeled cells among at least 500 cells per region was counted and then expressed as percentage values. For the quantification of mean vessel density in sections stained for CD31, 10 random 0.159-mm 2 fields at Â100 magnification were captured for each tumor and microvessels were quantified. The data were expressed as mean F SE.
Western Blot Analysis To determine changes in indicated proteins, independent tumors from vehicle-treated (n = 3), bevacizumab-treated (n = 3 -4), 5-FU -treated (n = 2 -3), and bevacizumab/ 5-FU -treated (n = 4) mice were homogenized in buffer containing 20 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton X-100, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L h-glycerolphosphate, 2 mmol/L Na 3 VO 4 , 1 Ag/mL leupeptin, and 1 mmol/L phenylmethylsulfonyl fluoride. One hundred micrograms of tissue lysate were subjected to Western blot analysis as previously described (30) . Blots were incubated with indicated primary antibodies and 1:7,500 horseradish peroxidase -conjugated secondary antibodies. All primary antibodies were used at a final concentration of 1 Ag/mL. The blots were then visualized with a chemiluminescent detection system (Amersham) as described by the manufacturer. 
Statistical Analysis
To obtain the P values, the experiments were repeated thrice. Differences in tumor growth and expression of indicated proteins, tumor weight, Ki-67 index, mean vessel density, and cleaved caspase-3 -positive cells were analyzed by ANOVA.
Results
To study the effects of docetaxel, bevacizumab, 5-FU, and their combinations on prostate cancer growth, mice bearing CWR-22 and CWR-22R xenografts were treated with docetaxel, bevacizumab, 5-FU, bevacizumab/ docetaxel, and bevacizumab/5-FU. Both animal toxicity and the ability of these treatments to inhibit tumor formation and progression were determined. In preliminary studies, we found that treatment with a nonspecific antibody of the same immunoglobulin G isotype had no effect on tumor growth and was essentially equivalent to vehicle alone (data not shown). No overt toxicity of docetaxel, bevacizumab, 5-FU, and the combined therapies was observed during the course of treatment as defined by weight loss, unkempt appearance or mortality, and behavior (Fig. 1A) . The efficacy of docetaxel, bevacizumab, and 5-FU as determined by %T/C is shown in Fig. 1C . All the treatments significantly inhibited tumor growth (P < 0.01). Figure 1C shows that T/C ratio in bevacizumab/ 5-FU was <0.42 (Drug Evaluation Branch of the Division of Cancer Treatment, National Cancer Institute criteria), suggesting that this combination was very active. The androgen-dependent human CWR-22 was more sensitive than androgen-independent CWR-22R prostate cancer (Fig. 1C) . Because bevacizumab/5-FU combination exhibits higher antitumor activity than bevacizumab/docetaxel, this combination was selected for further studies.
We next examined the association between the antitumor activity of bevacizumab, 5-FU, and bevacizumab/5-FU treatments and their ability to inhibit blood vessel formation in prostate cancer xenografts. Bevacizumab (Fig. 2C) and bevacizumab/5-FU (Fig. 2D ) decreased blood vessels supplied to the tumors. Mild suppression of 5-FU on neovascularization was also noticed (Fig. 2B) . Table 1 shows the median number of CD31-positive tumor cells from vehicle-, bevacizumab-, 5-FU -, and bevacizumab/ 5-FU -treated tumors on day 21 during the treatment. The number of microvessels in bevacizumab-treated tumors was approximately 35% and 17% of that seen in vehicletreated tumors (Table 1) . Although bevacizumab/5-FU potently inhibited angiogenesis, we observed very little necrosis in bevacizumab/5-FU -treated tumors (data not shown). To examine the antiproliferative and apoptotic effects of bevacizumab, 5-FU, and combined bevacizumab/5-FU treatments in vivo, sections were stained with Ki-67 and cleaved caspase-3 antibodies. Table 1 shows that the Ki-67 labeling index in bevacizumab-, 5-FU -, and bevacizumab/ 5-FU -treated tumors was significantly decreased compared with vehicle-treated tumors (P < 0.01). Further decrease in number of cells stained with Ki-67 antibody was observed in the combined therapy. The percentage of cells stained for cleaved caspase-3 was significantly increased in 5-FU -treated (P < 0.01) but not in bevacizumab-or bevacizumab/5-FU -treated tumors, suggesting that bevacizumab and bevacizumab/5-FU did not cause any significant apoptosis (Table 1) .
Because PTEN deficiency leads to Akt activation and triggers initiation of prostate cancer (9), we determined whether bevacizumab/5-FU -inhitbed prostate cancer xenograft growth was associated with changes in these proteins. Figure 3 shows that whereas 5-FU had no effect on PTEN expression and Akt phosphorylation, bevacizumab slightly increased phosphorylation of Akt at Ser 473 . Whereas PTEN expression in bevacizumab/5-FU -treated samples was increased by 3.6-fold (P < 0.01), phosphorylation of Akt at Thr 308 and Ser 473 was significantly decreased (P < 0.01; Fig. 3 ), suggesting that Akt was inactivated.
Because phosphatidylinositol 3-kinase/Akt -stimulated oncogenesis is dependent on mTOR (32), and downstream targets of mTOR play an important role in regulating cell cycle progression (33) and angiogenesis (reviewed in ref. 34 ), the expression of positive and negative cell cycle regulators and the abundance of phosphorylation of mTOR, p70S6 kinase, and 4E-BP1 were investigated. Figure 3 shows that the levels of phospho-mTOR at Ser 2448 , phospho-p70S6 kinase at Thr 421 /Ser 424 , and phospho-4E-BP1 at Thr 37/46 and Thr 70 in tumors derived from mice treated with bevacizumab/5-FU, but not bevacizumab or 5-FU, were significantly decreased (P < 0.01). Total 4E-BP1, mTOR, and p70S6 kinase was not altered by any treatments, suggesting that the mTOR pathway is inactivated. Figure 4 shows that a slight increase in cyclin D1 was seen in bevacizumab-treated samples. Cyclin B1, cyclin A, Cdk-2, and Cdk-4 expression was not affected by 5-FU or bevacizumab treatment. The levels of positive regulators Cdk-2 and Cdk-4 in bevacizumab/5-FU -treated tumors were significantly decreased (P < 0.01). Up-regulation of p21 
Discussion
Despite tremendous efforts and resources devoted to treatment, the incidence and mortality of prostate cancer have not decreased in the past decades because prostate cancer cells are barely responsive to chemotherapeutic agents or radiotherapy (reviewed in ref. 6 ). Although patients with metastatic prostate cancer can benefit from androgen ablation, most of them will die of prostate cancer progression to an androgen-refractory state. Therefore, an effective treatment strategy against prostate cancer is needed to spare the burden of the patients. In the present study, we show that bevacizumab, docetaxel, and 5-FU, when given as single agents, inhibit the growth of both androgen-dependent and androgen-independent prostate cancer xenografts. The growth of prostate cancer xenografts is further suppressed when bevacizumab is given with 5-FU but not docetaxel. Bevacizumab/5-FU up-regulates . Mean vessel density, Ki-67 index, and apoptosis in the tumors at harvest (day 21 during treatment) were determined by immunohistochemical staining with antibodies against CD31, Ki-67, and cleaved caspase-3, respectively. The data are expressed as mean F SE. Differences in tumor weight, microvessel density, Ki-67 index, and cleaved caspase-3 between vehicle, bevacizumab, 5-FU, and bevacizumab/5-FU groups were analyzed by ANOVA. Different superscript letter indicates significant difference between values (P < 0.01). * Mean microvessel density of 10 random 0.159-mm 2 fields at Â100 magnification. 1 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).
PTEN, an upstream down-regulator of phosphatidylinositol 3-kinase/Akt, and inhibits the phosphorylation of Akt, an upstream positive modulator of mTOR, leading to inactivation of p70S6 kinase and 4E-BP1. In addition, bevacizumab/5-FU also enhances the expression of p21 Cip1/Waf1 , p16 INK4a , and p27 Kip1 , resulting in hypophosphorylation of retinoblastoma. These events may contribute to its potent growth inhibition. By inhibiting protein synthesis, cell cycle progression, and angiogenesis, bevacizumab/5-FU therapy may prove to be useful in maintaining dormancy of micrometastasis and preventing the development of overt recurrence or metastasis after surgical resection of a primary tumor.
Both 5-FU and bevacizumab, when administered as single agents, reduced but did not fully suppress the growth of CWR-22R and CWR-22 prostate cancer xenografts. However, bevacizumab/5-FU significantly suppressed prostate cancer growth to a greater degree than single-agent therapy. The mechanism of action of bevacizumab/5-FU is likely to be multifactorial and should be further investigated using different approaches. Recently, studies have discovered that the mTOR pathway regulates tumor angiogenesis as it stimulates VEGF production by tumor cells (35) . It is possible that combined suppression of both VEGF protein (by bevacizumab) and VEGF expression (by targeting mTOR via bevacizumab/5-FU) might induce a synergistic inhibition of prostate tumor angiogenesis. Thus, one function of bevacizumab/5-FU is to prevent the tumor mass from expanding by preventing further development of the tumor neovascular network. It has been Bevacizumab/5-FU Inhibits Prostate Cancer Growth 2154 reported that tumor-associated endothelial cells are targets of bevacizumab in vivo. These cells express VEGF receptor and require VEGF for proliferation and survival (36) . With the inhibition of activity by bevacizumab and VEGF production by bevacizumab/5-FU through inhibition of mTOR, tumor-associated endothelial cells, whose proliferating frequency is 20 to 2,000 times higher than that of endothelial cells in normal organs (37, 38) , would be more sensitive to the combined bevacizumab/5-FU treatment. Supporting this hypothesis, we observe that bevacizumab/ 5-FU -treated tumors have a gross reduction in blood supply (Fig. 2D ) and fewer visible blood vessels compared with bevacizumab and 5-FU.
We have shown that docetaxel, when given at a dose of 10 mg/kg per week for 2 weeks, has moderate activity against prostate cancer growth. This is in agreement with the previous study (31) . Our present study shows that bevacizumab, when given together with 5-FU, was far more effective than monotherapy in treatment of prostate cancer. Our data, coupled with previous reports (20, 31, 39) , suggest that in prostate cancer, targeting different pathways using both biological and cytotoxic compounds is needed. The safety and efficacy of bevacizumab/docetaxel/estramustine combination for hormone-refractory prostate cancer have been reported (reviewed in ref. 21 ). In the present study, we observe that docetaxel does not enhance the antitumor activity of bevacizumab. Experiments are under way to determine why this combination fails.
Dysregulation of cell cycle control mechanism is an important carcinogenic mechanism. The p16
INK4a /cyclin D1/pRb pathway is a major regulator of the cell cycle (reviewed in ref. 40) . Whereas bevacizumab/5-FU regulates the expression of several cell cycle -related components, including up-regulation of p21
Cip1/Waf1 , p16 INK4a , and p27
Kip1 and inhibition of pRb phosphorylation (P < 0.01; Fig. 4 ), such synergistic effects are not observed when 5-FU or bevacizumab was used as monotherapy, suggesting that bevacizumab/5-FU also inhibits cell cycle progression. In addition, bevacizumab/5-FU may also block cell cycle progression by inhibiting the Akt activity and downstream effectors of mTOR, p70S6 kinase, and 4E-BP1. Inactivation of mTOR pathway may lead to decreased translation of mRNAs encoding positive regulators of cell cycle progression, such as cyclin D1, and to increased translation of negative regulators such as p27 Kip1 , as previously reported (11, 41) .
Our data show that addition of bevacizumab to 5-FUbased chemotherapy potently inhibits the Akt/mTOR pathway. This observation has clinical implications because the growth and proliferation of the tumors with Akt activation and/or PTEN loss display enhanced sensitivity to rapamycin and analogues (42) . These suggest that inhibition of Akt/mTOR activity by bevacizumab/5-FU could significantly contribute to treatment of prostate cancer. Apart from rapamycin and its analogues, CCI-779 and RAD001, no chemotherapeutic drugs used in treatment of prostate cancer effectively inhibit mTOR and its downstream targets. To enhance the antitumor effect of bevacizumab/5-FU, it is also worth considering to include mTOR inhibitors, such as CCI-779 and RAD001 (32, 43 -45) , to bevacizumab/5-FU regimen especially for patients with nonfunctional PTEN tumors or patients with metastasis and hormone-refractory tumors. Although our preclinical data hold much promise, clinical trials are needed to determine whether bevacizumab/5-FU is as effective as docetaxel/prednisone (reviewed in ref. 6) or docetaxel/ trastuzumab combination (39) in therapy for metastatic hormone-refractory prostate cancer.
